## Guillermo Ruiz-Irastorza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1335296/publications.pdf

Version: 2024-02-01

239 papers

22,490 citations

20817 60 h-index 9345

265 all docs 265
docs citations

265 times ranked 15623 citing authors

g-index

#	Article	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
2	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	5.6	1,098
3	Antiphospholipid syndrome. Lancet, The, 2010, 376, 1498-1509.	13.7	916
4	Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Annals of the Rheumatic Diseases, 2010, 69, 20-28.	0.9	817
5	Systemic lupus erythematosus. Nature Reviews Disease Primers, 2016, 2, 16039.	30.5	816
6	The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Annals of the Rheumatic Diseases, 2016, 75, 795-810.	0.9	780
7	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.9	759
8	EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases, 2019, 78, 1296-1304.	0.9	664
9	Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Research and Therapy, 2006, 8, 209.	3.5	469
10	Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies. Lupus, 2011, 20, 206-218.	1.6	467
11	Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology, 2008, 47, 920-923.	1.9	396
12	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1706-1713.	0.9	391
13	The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology, 2016, 55, 252-262.	1.9	370
14	Morbidity and Mortality in Systemic Lupus Erythematosus During a 5-Year Period: A Multicenter Prospective Study of 1,000 Patients. Medicine (United States), 1999, 78, 167-175.	1.0	367
15	Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus, 2006, 15, 577-583.	1.6	351
16	INCREASED RATE OF LUPUS FLARE DURING PREGNANCY AND THE PUERPERIUM: A PROSPECTIVE STUDY OF 78 PREGNANCIES. Rheumatology, 1996, 35, 133-138.	1.9	306
17	A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis and Rheumatism, 2007, 57, 1487-1495.	6.7	294
18	Predictors of major infections in systemic lupus erythematosus. Arthritis Research and Therapy, 2009, 11, R109.	3.5	288

#	Article	IF	CITATIONS
19	Autoimmune diseases induced by biological agents. Autoimmunity Reviews, 2010, 9, 188-193.	5.8	282
20	Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus, 2013, 22, 1286-1294.	1.6	274
21	Systemic lupus erythematosus. Lancet, The, 2001, 357, 1027-1032.	13.7	271
22	Cancer risk in systemic lupus: An updated international multi-centre cohort study. Journal of Autoimmunity, 2013, 42, 130-135.	6.5	249
23	Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy. Medicine (United States), 2011, 90, 359-371.	1.0	247
24	Antiphospholipid syndrome. Nature Reviews Disease Primers, 2018, 4, 17103.	30.5	233
25	Antiphospohlipid syndrome in obstetrics. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 65-76.	2.8	218
26	Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmunity Reviews, 2012, 11, 357-364.	5.8	209
27	High Impact of Antiphospholipid Syndrome on Irreversible Organ Damage and Survival of Patients With Systemic Lupus Erythematosus. Archives of Internal Medicine, 2004, 164, 77.	3.8	195
28	Glucocorticoid use and abuse in SLE. Rheumatology, 2012, 51, 1145-1153.	1.9	186
29	State of the art: Reproduction and pregnancy in rheumatic diseases. Autoimmunity Reviews, 2015, 14, 376-386.	5.8	169
30	Assessing disease activity in SLE patients during pregnancy. Lupus, 1999, 8, 677-684.	1.6	166
31	Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology, 2014, 53, 1470-1476.	1.9	166
32	Bleeding and Recurrent Thrombosis in Definite Antiphospholipid Syndrome. Archives of Internal Medicine, 2002, 162, 1164.	3.8	163
33	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1502-1509.	0.9	143
34	Biologics-induced autoimmune diseases. Current Opinion in Rheumatology, 2013, 25, 56-64.	4.3	143
35	A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases. Medicine (United States), 2008, 87, 345-364.	1.0	136
36	Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2011, 70, 1726-1732.	0.9	132

#	Article	IF	Citations
37	Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage. Arthritis Care and Research, 2010, 62, 1160-1165.	3.4	121
38	Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the "Euro-Lupus Project― Autoimmunity Reviews, 2006, 5, 180-186.	5.8	115
39	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Annals of the Rheumatic Diseases, 2014, 73, 138-142.	0.9	115
40	Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatology, 2011, 50, 657-664.	1.9	112
41	SYSTEMIC LUPUS ERYTHEMATOSUS FLARES DURING PREGNANCY. Rheumatic Disease Clinics of North America, 1997, 23, 15-30.	1.9	107
42	Anti-C1q antibodies in systemic lupus erythematosus. Lupus, 2015, 24, 42-49.	1.6	106
43	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	5.6	98
44	Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2007, 66, 815-817.	0.9	91
45	High risk of tuberculosis in systemic lupus erythematosus?. Lupus, 2006, 15, 232-235.	1.6	88
46	Management of antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2019, 78, 155-161.	0.9	85
47	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. Arthritis and Rheumatism, 2013, 65, 2887-2897.	6.7	84
48	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. Seminars in Arthritis and Rheumatism, 2019, 49, 464-468.	3.4	79
49	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2013, 72, 1308-1314.	0.9	78
50	Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus, 2003, 12, 508-513.	1.6	71
51	Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus, 2007, 16, 810-816.	1.6	71
52	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology, 2014, 53, 275-284.	1.9	71
53	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.9	70
54	Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	3.4	70

#	Article	IF	Citations
55	Measuring systemic lupus erythematosus activity during pregnancy: Validation of the lupus activity index in pregnancy scale. Arthritis and Rheumatism, 2004, 51, 78-82.	6.7	69
56	Prednisone in lupus nephritis: How much is enough?. Autoimmunity Reviews, 2014, 13, 206-214.	5.8	69
57	Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology, 2020, 59, v69-v81.	1.9	69
58	Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Longâ€Term Disease Control: An Observational Study. Arthritis Care and Research, 2018, 70, 582-591.	3.4	67
59	Lupus and pregnancy: ten questions and some answers. Lupus, 2008, 17, 416-420.	1.6	66
60	Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmunity Reviews, 2013, 12, 410-415.	5.8	66
61	The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Thrombosis and Haemostasis, 2016, 115, 285-290.	3.4	66
62	Risk Factors for Esophageal Candidiasis. European Journal of Clinical Microbiology and Infectious Diseases, 2000, 19, 96-100.	2.9	63
63	Hydroxychloroquine: the cornerstone of lupus therapy. Lupus, 2008, 17, 271-273.	1.6	63
64	Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus, 2004, 13, 900-905.	1.6	60
65	Lupus and pregnancy: integrating clues from the bench and bedside. European Journal of Clinical Investigation, 2011, 41, 672-678.	3.4	60
66	Comparison of high versus low–medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmunity Reviews, 2015, 14, 875-879.	5.8	57
67	Pulmonary Disorders Induced by Monoclonal Antibodies in Patients with Rheumatologic Autoimmune Diseases. American Journal of Medicine, 2011, 124, 386-394.	1.5	55
68	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	3.4	55
69	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	<b>5.</b> 6	55
70	Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data. PLoS ONE, 2020, 15, e0239401.	2.5	54
71	Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues. Journal of Clinical Medicine, 2020, 9, 2709.	2.4	54
72	Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Research and Therapy, 2011, 13, R112.	3.5	53

#	Article	IF	Citations
73	Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmunity Reviews, 2017, 16, 826-832.	5.8	53
74	Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus, 2017, 26, 266-276.	1.6	53
75	Pseudochylothorax: Report of 2 Cases and Review of the Literature. Medicine (United States), 1999, 78, 200-207.	1.0	52
76	Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. Seminars in Arthritis and Rheumatism, 2016, 45, 391-399.	3.4	52
77	The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus, 2017, 26, 1051-1059.	1.6	52
78	Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Current Opinion in Rheumatology, 2018, 30, 482-489.	4.3	52
79	Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Science and Medicine, 2016, 3, e000163.	2.7	51
80	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 634-640.	0.9	51
81	Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Science and Medicine, 2016, 3, e000143.	2.7	50
82	Evaluation of systemic lupus erythematosus activity during pregnancy. Lupus, 2004, 13, 679-682.	1.6	49
83	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Selfâ€Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2018, 103, 1074-1082.	4.7	48
84	Management of Thrombosis in Antiphospholipid Syndrome and Systemic Lupus Erythematosus in Pregnancy. Annals of the New York Academy of Sciences, 2005, 1051, 606-612.	3.8	46
85	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.9	42
86	Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome. Lupus, 2001, 10, 241-245.	1.6	40
87	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis and Rheumatology, 2016, 68, 1932-1944.	5.6	40
88	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.9	40
89	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	5.6	39
90	High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome:  PROS' and  CONS'. Autoimmunity Reviews, 2012, 11, 577-580.	5.8	38

#	Article	IF	Citations
91	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	1.9	37
92	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Annals of the Rheumatic Diseases, 2021, 80, 775-781.	0.9	37
93	Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica, 2004, 89, ECR34.	3.5	37
94	Reversible bone marrow depression by highâ€dose piperacillin/tazobactam. British Journal of Haematology, 1996, 95, 611-612.	2.5	36
95	Managing lupus patients during pregnancy. Best Practice and Research in Clinical Rheumatology, 2009, 23, 575-582.	3.3	36
96	Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 2012, 38, 339-347.	2.7	35
97	Peripheral Arterial Disease in Systemic Lupus Erythematosus: Prevalence and Risk Factors. Journal of Rheumatology, 2014, 41, 310-317.	2.0	35
98	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases, 2020, 79, 1333-1339.	0.9	35
99	Lupus pregnancy: is heparin a risk factor for osteoporosis?. Lupus, 2001, 10, 597-600.	1.6	34
100	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 72-81.	2.0	34
101	Effectiveness of Nonpharmacologic Interventions for Decreasing Fatigue in Adults With Systemic Lupus Erythematosus: A Systematic Review. Arthritis Care and Research, 2016, 68, 141-148.	3.4	33
102	Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care and Research, 2012, 64, n/a-n/a.	3.4	32
103	Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort. Lupus, 2018, 27, 2253-2261.	1.6	32
104	Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. Autoimmunity Reviews, 2019, 18, 102359.	5.8	32
105	Update on therapy â€" thalidomide in the treatment of lupus. Lupus, 2001, 10, 188-192.	1.6	31
106	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. Annals of the Rheumatic Diseases, 2021, 80, 1.1-2.	0.9	31
107	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	2.7	31
108	Antiphospholipid Syndrome in Pregnancy. Rheumatic Disease Clinics of North America, 2007, 33, 287-297.	1.9	30

#	Article	IF	Citations
109	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <scp>SLE</scp> : Assessment by Drug Levels and Selfâ€Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2019, 106, 374-382.	4.7	30
110	Treatment of systemic lupus erythematosus. International Immunopharmacology, 2001, 1, 1065-1075.	3.8	29
111	Heparin and osteoporosis during pregnancy: 2002 update. Lupus, 2002, 11, 680-682.	1.6	28
112	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	6.5	27
113	Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus. Lupus, 2020, 29, 1155-1167.	1.6	27
114	Hughes syndrome crosses boundaries. Autoimmunity Reviews, 2002, 1, 43-48.	5 <b>.</b> 8	26
115	Treatment of pregnancy loss in Hughes syndrome: a critical update. Autoimmunity Reviews, 2002, 1, 298-304.	5.8	26
116	Stroke and antiphospholipid syndrome: the treatment debate. Rheumatology, 2005, 44, 971-974.	1.9	26
117	Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. Arthritis Care and Research, 2018, 70, 98-103.	3.4	26
118	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	5 <b>.</b> 6	26
119	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	5.6	25
120	Breast Cancer in Systemic Lupus Erythematosus. Oncology, 2013, 85, 117-121.	1.9	24
121	Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus. Autoimmunity Reviews, 2016, 15, 1134-1140.	5.8	24
122	Combined mepacrine–hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. Lupus, 2018, 27, 1718-1722.	1.6	24
123	LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers. PLoS ONE, 2016, 11, e0146990.	2.5	24
124	Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). Nefrologia, 2012, 32 Suppl 1, 1-35.	0.4	24
125	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	3.4	23
126	Does SLE flare during pregnancy?. Scandinavian Journal of Rheumatology, 1998, 27, 76-79.	1.1	22

#	Article	IF	CITATIONS
127	Septic Shock Due to Pasteurella multocida Subspecies multocida in a Previously Healthy Woman. Clinical Infectious Diseases, 1995, 21, 232-234.	5.8	21
128	Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus, 2004, 13, 927-933.	1.6	21
129	Breast cancer in systemic lupus. Lupus, 2017, 26, 311-315.	1.6	21
130	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	3.4	21
131	First month prednisone dose predicts prednisone burden during the following 11â€months: an observational study from the RELES cohort. Lupus Science and Medicine, 2016, 3, e000153.	2.7	20
132	Cognitive Impairment in Patients With Neuropsychiatric and Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis. Journal of the International Neuropsychological Society, 2018, 24, 629-639.	1.8	20
133	Patient participation in a Clinical Guideline Development for Systemic Lupus Erythematosus. Patient Education and Counseling, 2015, 98, 1156-1163.	2.2	19
134	Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus. Lupus, 2019, 28, 555-559.	1.6	19
135	Granulocyte Colony-Stimulating Factor for Neutropenia Secondary to Ticlopidine. Acta Haematologica, 1994, 91, 106-107.	1.4	18
136	Hepatotoxicity Associated with Penicillin V Therapy. Clinical Infectious Diseases, 1995, 20, 474-475.	5.8	18
137	Warfarin for multiple sclerosis?. QJM - Monthly Journal of the Association of Physicians, 2000, 93, 497-499.	0.5	18
138	Therapy of systemic lupus erythematosus: new agents and new evidence. Expert Opinion on Investigational Drugs, 2000, 9, 1581-1593.	4.1	18
139	The treatment of antiphospholipid syndrome: A harmonic contrast. Best Practice and Research in Clinical Rheumatology, 2007, 21, 1079-1092.	3.3	18
140	Thrombotic Antiphospholipid Syndrome Shows Strong Haplotypic Association with SH2B3-ATXN2 Locus. PLoS ONE, 2013, 8, e67897.	2.5	18
141	Update on antimalarials and systemic lupus erythematosus. Current Opinion in Rheumatology, 2020, 32, 572-582.	4.3	18
142	Rituximab-refractory lupus nephritis successfully treated with belimumab. Clinical and Experimental Rheumatology, 2016, 34, 355-6.	0.8	18
143	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	5.6	17
144	Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis. Autoimmunity Reviews, 2021, 20, 102898.	5.8	17

#	Article	IF	CITATIONS
145	Prosthetic-Valve Endocarditis Caused by Peptostreptococcus anaerobius. Clinical Infectious Diseases, 1995, 20, 1431-1431.	5.8	15
146	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. Journal of Rheumatology, 2019, 46, 492-500.	2.0	15
147	Systemic lupus erythematosus and antiphospholipid syndrome during pregnancy: maternal and fetal complications and their management. Israel Medical Association Journal, 2000, 2, 462-9.	0.1	15
148	Systemic lupus erythematosus presenting as acute symptomatic hypercalcemia. Lupus, 2004, 13, 132-134.	1.6	14
149	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology, 2021, 60, 4737-4747.	1.9	14
150	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care and Research, 2021, 73, 1789-1795.	3.4	13
151	Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone. Lupus, 2014, 23, 323-326.	1.6	12
152	Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?. Current Rheumatology Reports, 2016, 18, 26.	4.7	12
153	Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres. Lupus Science and Medicine, 2018, 5, e000274.	2.7	12
154	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.9	12
155	Trends in Hospital Admissions and Death Causes in Patients with Systemic Lupus Erythematosus: Spanish National Registry. Journal of Clinical Medicine, 2021, 10, 5749.	2.4	11
156	Polyarteritis Nodosa Presenting as Ischaemic Colitis. Rheumatology, 1996, 35, 1333-1334.	1.9	9
157	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). Arthritis Care and Research, 2020, , .	3.4	9
158	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.9	9
159	Neurosyphilis as a cause of dementia. Does it still exist?. Journal of Infection, 1995, 30, 186-187.	3.3	8
160	Aspirin to treat obstetric manifestations of the antiphospholipid syndrome. American Journal of Obstetrics and Gynecology, 2001, 185, 523-524.	1.3	8
161	SLE: the changing prognosis. Lupus, 2016, 25, 1285-1287.	1.6	8
162	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	1.9	8

#	Article	IF	CITATIONS
163	Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management. Medicina ClÃnica (English Edition), 2016, 146, 413.e1-413.e14.	0.2	7
164	Anti-phospholipid antibodies do not predict damage in SLE patients in the 21st century—an observational study from the Lupus-Cruces cohort. Rheumatology, 2021, 61, 249-257.	1.9	7
165	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	5.6	7
166	Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2016, 34, 466-72.	0.8	7
167	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	3.4	7
168	Predictors of peripheral arterial disease in SLE change with patient's age. Lupus Science and Medicine, 2017, 4, e000190.	2.7	6
169	Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up. ReumatologÃa ClÃnica (English Edition), 2021, 17, 125-131.	0.3	6
170	Prednisone in systemic lupus erythematosus: taper quickly, withdraw slowly. Rheumatology, 2021, 60, 5489-5490.	1.9	6
171	Prevention and Treatment of Thrombotic Antiphospholipid Syndrome. , 2017, , 223-233.		6
172	AB0542â€Blocking the Human B Lymphocyte Stimulator Molecule (BLYS) Using A Monoclonal Antibody (Belimumab) in Systemic Lupus Erythematosus: First Results in Real-Life Spanish Patients with Refractory Disease (Biogeas-Semi Registry). Annals of the Rheumatic Diseases, 2014, 73, 985.2-985.	0.9	5
173	CaracterÃsticas clÃnicas al diagnÃ <sup>3</sup> stico de una cohorte prospectiva de pacientes con lupus eritematoso sistémico atendidos en servicios de Medicina Interna españoles: estudio RELES. Revista Clinica Espanola, 2017, 217, 7-14.	0.6	5
174	Control del embarazo en pacientes con lupus eritematoso sistÃ@mico/sÃndrome antifosfolÃpido. parte 2: seguimiento del embarazo. ReumatologÃa ClÃnica, 2021, 17, 125-131.	0.5	5
175	Chronic Osteomyelitis Caused by Salmonella fyris. Clinical Infectious Diseases, 1994, 19, 221-221.	5.8	4
176	Treatment of the antiphospholipid syndrome in pregnancy. Scandinavian Journal of Rheumatology, 1998, 27, 44-47.	1.1	4
177	Gastroesophageal Reflux Disease. New England Journal of Medicine, 2009, 360, 729-730.	27.0	4
178	Antiphospholipid Antibodies and Risk for Recurrent Vascular Events. JAMA - Journal of the American Medical Association, 2004, 291, 2701.	7.4	4
179	Management of Thrombosis in Antiphospholipid Syndrome. , 2006, , 547-554.		4
180	Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients. Clinical and Experimental Rheumatology, 2015, 33, S-90-7.	0.8	4

#	Article	IF	Citations
181	Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines. European Journal of Internal Medicine, 2022, 99, 19-21.	2.2	4
182	Control del embarazo en pacientes con lupus eritematoso sistémico y sÃndrome antifosfolÃpido. Parte 1: Infertilidad, preservación ovárica y valoración preconcepcional. Documento de consenso de la Sociedad Española de GinecologÃa y Obstetricia (SEGO), Sociedad Española de Medicina Interna (SEMI) y Sociedad Española de ReumatologÃa (SER). ReumatologÃa ClÃnica, 2021, 17, 61-66.	0.5	3
183	Control del embarazo en pacientes con lupus eritematoso sistémico/sÃndrome antifosfolÃpido. Parte 3. Parto. Puerperio. Lactancia. Anticoncepción. Recién nacido. ReumatologÃa ClÃnica, 2021, 17, 183-186.	0.5	3
184	Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 3: Childbirth. Puerperium. Breastfeeding contraception. Newborn. ReumatologÃa ClÃnica (English) Tj ETQqO 0 0 rgE	3T <b>¢Q</b> verlo	ckal 0 Tf 50 6
185	Heart Disease, Pregnancy and Systemic Autoimmune Diseases. , 0, , 136-150.		3
186	Antiphospholipid syndrome: treatment controversies. Future Rheumatology, 2006, 1, 345-353.	0.2	3
187	Transplantation-mediated alloimmune thrombocytopenia successfully treated by retransplantation. Lupus, 2021, 30, 669-673.	1.6	3
188	Temporal Artery Biopsy and Corticosteroid Treatment: Changing Conclusions without Changing Evidence. Annals of Internal Medicine, 1997, 127, 248.	3.9	2
189	A new role for antimalarials in systemic lupus erythematosus treatment. International Journal of Clinical Rheumatology, 2010, 5, 299-312.	0.3	2
190	Cardiopulmonary Disease in SLE. , 2013, , 352-362.		2
191	Can we effectively treat lupus and reduce the side-effects of glucocorticoids?. Lancet Rheumatology, The, 2020, 2, e3-e5.	3.9	2
192	HomocisteÃna plasmática en pacientes con lupus eritematoso sistémico. Medicina ClÃnica, 2003, 120, 681-685.	0.6	2
193	Subacute Pneumococcal Endocarditis. Clinical Infectious Diseases, 1998, 27, 1341-1341.	5.8	1
194	Biologics use in sle in 23 centers – data from the international registry for biologics in SLE. Annals of the Rheumatic Diseases, 2012, 71, A9.1-A9.	0.9	1
195	Prevalence and Significance of Persistently Positive Antiphospholipid Antibodies in Women with Preeclampsia. Journal of Rheumatology, 2015, 42, 210-213.	2.0	1
196	Pregnancy in systemic autoimmune diseases: Myths, certainties and doubts. Medicina ClÃnica (English) Tj ETQqC	0.0 rgBT	/Oyerlock 10
197	THU0304â€Adherence To Hydroxychloroquine as Assessed by Measurements of Drug and Metabolite Blood Levels in An International Prospective Study of Sle Patients in Flare. Annals of the Rheumatic Diseases, 2016, 75, 297.1-297.	0.9	1
198	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	3.5	1

#	Article	IF	CITATIONS
199	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology, 2018, 57, 1501-1502.	1.9	1
200	Hydroxychloroquine Retinal Toxicity and Its Association with Dosage. Journal of Rheumatology, 2021, 48, 150-150.	2.0	1
201	What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. Lupus Science and Medicine, 2021, 8, e000506.	2.7	1
202	OP0289 LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON-MULTINATIONAL MULTICENTER COHORT. Annals of the Rheumatic Diseases, 2021, 80, 177-178.	OR) Tj ET( 0.9	2q0 0 0 rgBT 1
203	Vitamin Supplementation and Risk of Stroke. JAMA - Journal of the American Medical Association, 2004, 291, 2191.	7.4	1
204	Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome., 2012,, 167-179.		1
205	What are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome?. Expert Review of Clinical Immunology, 2022, 18, 779-781.	3.0	1
206	Antiphospholipid Testing and Outcomeâ€"Reply. Archives of Internal Medicine, 2004, 164, 1701.	3.8	0
207	Comments on the Editorial "Antiphospholypid Syndrome: New Clinical and Therapeutic Perspectives― ReumatologÃa ClÃnica (English Edition), 2007, 3, 90.	0.3	O
208	Chapter 15 Treatment of Thrombosis in the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2009, , 185-191.	0.1	0
209	Diagnóstico y tratamiento de la nefritis lúpica: el camino del consenso. Revista Clinica Espanola, 2012, 212, 155-156.	0.6	O
210	Belimumab en el lupus eritematoso sistémico: una guÃa para su uso en la práctica diaria. Revista Clinica Espanola, 2013, 213, 66-67.	0.6	0
211	Gastroesophageal Reflux Disease. Gastroenterology Research and Practice, 2013, 2013, 1-2.	1.5	O
212	Managing Lupus Nephritis in Pregnant Women: Comment on the Article by Hahn et al. Arthritis Care and Research, 2013, 65, 1391-1392.	3.4	0
213	SATO199â€An estimate of the proportion of patients with sle receiving off-label treatment with rituximab in european countries. Annals of the Rheumatic Diseases, 2013, 71, 539.1-539.	0.9	O
214	Dr. Erdozain, <i>et al</i> reply. Journal of Rheumatology, 2014, 41, 2086.2-2086.	2.0	0
215	Cancer risk factors in systemic lupus erythematosus: multivariate regression analysis in 16,409 patients. Arthritis Research and Therapy, 2014, 16, A35.	3.5	O
216	SATO2O2â€International Multi-Centre Study to Evaluate the Clinical Significance of Phosphatidylserine-Dependent Antiprothrombin Antibodies for the Diagnosis of Antiphospholipid Syndrome. Annals of the Rheumatic Diseases, 2014, 73, 662.3-663.	0.9	O

#	Article	IF	CITATIONS
217	Treatment of Thrombosis in Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, 12, 231-241.	0.1	O
218	Clinical characteristics during diagnosis of a prospective cohort of patients with systemic lupus erythematosus treated in Spanish Departments of Internal Medicine: The RELES study. Revista Clínica Espanõla, 2017, 217, 7-14.	0.5	0
219	FRIO284â€Predictors of arterial vascular events in a cohort of systemic lupus erythematosus. , 2017, , .		O
220	OP0002â€Multicriteria decision analysis for developing new classification criteria for systemic lupus erythematosus. , 2017, , .		O
221	CS-07â€Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
222	OP0252â€NEUROPATHIES IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM AN INTERNATIONAL, INCEPTION COHORT STUDY. , 2019, , .		0
223	P.368 Neuropsychiatric symptoms in patients with systemic lupus erythematosus: prevalence and its impact on quality of life. European Neuropsychopharmacology, 2020, 40, S211-S212.	0.7	0
224	Clinical presentation of antiphospholipid syndrome. , 2021, , 561-574.		0
225	Christmas Day in London: darling, I'm pregnant. BMJ: British Medical Journal, 2000, 321, 1539-1539.	2.3	O
226	THU0271â€PERFORMANCE OF THE EULAR/ACR 2019 CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN EARLY DISEASE, ACROSS SEXES AND ETHNICITIES. Annals of the Rheumatic Diseases, 2020, 79, 362.1-362.	0.9	0
227	FRIO152â€PULMONARY HYPERTENSION IN NEWLY DIAGNOSED SPANISH PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM THE RELES COHORT. Annals of the Rheumatic Diseases, 2020, 79, 660.2-660.	0.9	O
228	THU0256â€CARDIAC INVOLVEMENT IN NEWLY DIAGNOSED SPANISH PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM THE RELES COHORT. Annals of the Rheumatic Diseases, 2020, 79, 355.1-355.	0.9	0
229	1124â€Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		O
230	1107â€Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
231	1704â€ldentifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		O
232	Interstitial Lung Disease Associated with Connective Tissue Disease (CTD-ILD): Retrospective Multicentric Study., 2020,,.		0
233	Comparative study between two European inception cohorts of patients with early systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2020, 38, 925-932.	0.8	O
234	Ankle-brachial index and arterial vascular events in systemic lupus erythematosus patients: a 5-year prospective cohort. Clinical and Experimental Rheumatology, 2020, 38, 978-984.	0.8	0

#	Article	IF	CITATIONS
235	P.0738 Mood and anxiety disorders in Systemic Lupus Erythematosus: results and insights from the Lupus-Cruces cohort. European Neuropsychopharmacology, 2021, 53, S538-S539.	0.7	O
236	Title is missing!. , 2020, 15, e0239401.		0
237	Title is missing!. , 2020, 15, e0239401.		O
238	Title is missing!. , 2020, 15, e0239401.		0
239	Title is missing!. , 2020, 15, e0239401.		0